Difference between revisions of "Changing business models for pharmaceutical industry"

From ScenarioThinking
Jump to navigation Jump to search
m
(GaMOX1 <a href="http://iqlvgztznwqt.com/">iqlvgztznwqt</a>, [url=http://hncjlqeqbhrl.com/]hncjlqeqbhrl[/url], [link=http://rrjddzgcysui.com/]rrjddzgcysui[/link], http://dulbklunnfnm.com/)
Line 1: Line 1:
'''This page is under construction and edited by Murat Akguc EMBA09. In case of any questions/remarks, feel free to [mailto:murat.akguc@gmail.com contact me]'''
'''This page is under construction and edited by Murat Akguc EMBA09. In case of any questions/remarks, feel free to [mailto:murat.akguc@gmail.com contact me]'''


==Description:==
GaMOX1  <a href="http://iqlvgztznwqt.com/">iqlvgztznwqt</a>, [url=http://hncjlqeqbhrl.com/]hncjlqeqbhrl[/url], [link=http://rrjddzgcysui.com/]rrjddzgcysui[/link], http://dulbklunnfnm.com/
 
The pharmaceutical industry as we know it today will be radically
transformed. The conventional wisdom of producing blockbusters and
securing strong, stable earnings under patent protection is no longer
a foolproof success formula.
 
Pharmaceutical companies are hemmed in from two directions. On
one end, they are entering a period of thinning drug development
pipelines, patent expirations and competition from generics1. On the
other end, the increasing influence of the patient in making healthcare
decisions and the emergence of new intermediaries and service
providers undermine the traditional physician-pharmaceutical sales
representative relationship as the main channel through which drug
choices are influenced and made.[1]


==Enablers:==
==Enablers:==

Revision as of 10:04, 29 May 2010

This page is under construction and edited by Murat Akguc EMBA09. In case of any questions/remarks, feel free to contact me

GaMOX1 <a href="http://iqlvgztznwqt.com/">iqlvgztznwqt</a>, [url=http://hncjlqeqbhrl.com/]hncjlqeqbhrl[/url], [link=http://rrjddzgcysui.com/]rrjddzgcysui[/link], http://dulbklunnfnm.com/

Enablers:

Inhibitors:

Paradigms:

Big Pharma Companies will need to improve their R&D productivity, reduce their costs, tap the potential of the emerging economies and switch from selling medicines to managing outcomes.

Experts:

Sources for additional information about this driving force. (if you have found people, put the links to them)

Timing:

Web Resources:

[1] Business Model of the Information Age Pharmaceutical Industry, The Information Management Group (http://www.img.ch/upload/63001e_White_Paper_Business_Model_of_the_Information_AGE_-_Pharmaceutical_Industry_282.pdf)